Advertisement
Loading...

InflaRx N.V.

IFRXNASDAQ
Healthcare
Biotechnology
$2.52
$0.09(3.70%)
U.S. Market opens in 3h 49m

InflaRx N.V. Fundamental Analysis

InflaRx N.V. (IFRX) shows weak financial fundamentals with a PE ratio of -3.89, profit margin of -1462.51%, and ROE of -91.12%. The company generates $0.0B in annual revenue with weak year-over-year growth of -83.01%.

Key Strengths

Cash Position21.87%
PEG Ratio-0.25
Current Ratio4.16

Areas of Concern

ROE-91.12%
Operating Margin-1521.68%
We analyze IFRX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -109833.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-109833.3/100

We analyze IFRX's fundamental strength across five key dimensions:

Efficiency Score

Weak

IFRX struggles to generate sufficient returns from assets.

ROA > 10%
-84.19%

Valuation Score

Excellent

IFRX trades at attractive valuation levels.

PE < 25
-3.89
PEG Ratio < 2
-0.25

Growth Score

Moderate

IFRX shows steady but slowing expansion.

Revenue Growth > 5%
-83.01%
EPS Growth > 10%
15.38%

Financial Health Score

Excellent

IFRX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.02
Current Ratio > 1
4.16

Profitability Score

Weak

IFRX struggles to sustain strong margins.

ROE > 15%
-9111.80%
Net Margin ≥ 15%
-1462.51%
Positive Free Cash Flow
No

Key Financial Metrics

Is IFRX Expensive or Cheap?

P/E Ratio

IFRX trades at -3.89 times earnings. This suggests potential undervaluation.

-3.89

PEG Ratio

When adjusting for growth, IFRX's PEG of -0.25 indicates potential undervaluation.

-0.25

Price to Book

The market values InflaRx N.V. at 4.34 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

4.34

EV/EBITDA

Enterprise value stands at -3.69 times EBITDA. This is generally considered low.

-3.69

How Well Does IFRX Make Money?

Net Profit Margin

For every $100 in sales, InflaRx N.V. keeps $-1462.51 as profit after all expenses.

-1462.51%

Operating Margin

Core operations generate -1521.68 in profit for every $100 in revenue, before interest and taxes.

-1521.68%

ROE

Management delivers $-91.12 in profit for every $100 of shareholder equity.

-91.12%

ROA

InflaRx N.V. generates $-84.19 in profit for every $100 in assets, demonstrating efficient asset deployment.

-84.19%

Following the Money - Real Cash Generation

Operating Cash Flow

InflaRx N.V. generates limited operating cash flow of $-28.81M, signaling weaker underlying cash strength.

$-28.81M

Free Cash Flow

InflaRx N.V. generates weak or negative free cash flow of $-28.93M, restricting financial flexibility.

$-28.93M

FCF Per Share

Each share generates $-0.40 in free cash annually.

$-0.40

FCF Yield

IFRX converts -18.06% of its market value into free cash.

-18.06%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-3.89

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.25

vs 25 benchmark

P/B Ratio

Price to book value ratio

4.34

vs 25 benchmark

P/S Ratio

Price to sales ratio

5684.67

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.02

vs 25 benchmark

Current Ratio

Current assets to current liabilities

4.16

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.91

vs 25 benchmark

ROA

Return on assets percentage

-0.84

vs 25 benchmark

ROCE

Return on capital employed

-1.14

vs 25 benchmark

How IFRX Stacks Against Its Sector Peers

MetricIFRX ValueSector AveragePerformance
P/E Ratio-3.8929.12 Better (Cheaper)
ROE-91.12%726.00% Weak
Net Margin-146251.11%-41737.00% (disorted) Weak
Debt/Equity0.020.47 Strong (Low Leverage)
Current Ratio4.164.40 Strong Liquidity
ROA-84.19%-16472.00% (disorted) Weak

IFRX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews InflaRx N.V.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

54.49%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

62.65%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ